

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Basel, Switzerland, 24 April 2023. Pureos Bioventures' portfolio company Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer.

Dr. Lars Nieba brings more than 25 years of experience in biopharmaceutical leadership in R&D, business and clinical development, venture capital, manufacturing and product strategy and has been CEO and a Scientific Advisor to a number of biotechnology companies. Dr. Nieba has held previous positions in small and large biopharmaceutical companies including Roche and Bayer, where he touched a wide variety of modalities in drug development, from small molecules, through to therapeutic proteins, antibodies and gene therapies.

Engimmune was founded as a spinout from Prof. Sai Reddy's lab at the Department of Biosystems Science and Engineering at the ETH Zürich. Engimmune uses cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment and potentially autoimmune disease. By combining genome editing, functional screening, deep sequencing and machine learning, Engimmune addresses major efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapies. TCR pioneer and industry veteran Dr. Bent Jakobsen, co-founder of Immunocore and Adaptimmune, is Chairman of the Board. Engimmune is backed by leading investors Pureos Bioventures and Novo Holdings and was incubated at BaseLaunch, a leading European Biopharma incubator supported by Pureos Bioventures.

Lars Nieba, newly appointed Chief Executive Officer of Engimmune, said: *"I am looking forward to this exciting new role as the CEO of Engimmune Therapeutics. It is clear that the Company has an exciting future based on the significant potential of TCR-based therapies in oncology and immune mediated diseases. I am joining an excellent board and management team and I am confident that with my complementary experience and networks, we can succeed with its breakthrough TCR platform to develop next-generation treatments."*

Dominik Escher, Managing Partner at Pureos Bioventures and Member of the Board of Directors of Engimmune, commented: *"I am very pleased to welcome our Venture Partner Lars Nieba as CEO of Engimmune. His leadership, financial and biopharmaceutical expertise will be very instrumental as the company progresses to the next stages of development. There is immense untapped potential in TCR-based therapeutics which Engimmune's novel technologies and approach are ideally positioned to explore. We are looking forward to supporting Lars and the team at Engimmune on this journey"*

###

For further information, please contact:

Engimmune Therapeutics

e-mail: press@engimmune.com

Pureos Bioventures

e-mail: contact@pureosbio.com

About Engimmune Therapeutics AG

Engimmune Therapeutics is a technology platform and product-based company using cutting-edge technologies to engineer highly potent and specific T cell receptor (TCR) therapies. By applying proprietary platform technologies combining genome editing, functional high-throughput screening, deep sequencing and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics. The company was co-founded by Dr. Rodrigo Vazquez Lombardi, Prof. Sai Reddy and Dr. Søren Mouritsen in 2021 with the latter as CEO.

For more information, please visit www.engimmune.com.

About Pureos Bioventures

Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases.

For more information, please visit www.pureosbio.com.